With your support, we have been able to fund outstanding research, leading toward cures and improved quality of life for children with cancer. Browse through more than 1,000 funded projects below.
Use the search tool to refine your results. You can also click on a heading to sort by project title, institution name, or year the grant was awarded. Click on the project title to read more information.
You can learn about ALSF's grant review process here.
ALSF Funded Research Projects
|Project Title||Institution / Principal Investigator(s)||Grant Type||Year||State|
|Identifying Novel Therapeutic Combinations with 131I-MIBG to Treat Relapsed and Refractory Neuroblastoma||The Regents of the University of California San Francisco / William Clay Gustafson, M.D., Ph.D.||Reach Grants||2014||California|
|A Novel Target for Neuroblastoma Treatment||Beckman Research Institute of City of Hope / Linda Malkas, Ph.D.||Reach Grants||2014||California|
|Targeted Inhibition of the DNA Damage Response Pathway: A Novel Intervention in the Treatment of Pediatric Leukemias||National Cancer Institute / Andre Nussenzweig, Ph.D.||Reach Grants||2014||Maryland|
|DNA Methylation Inhibitor Therapy for Testicular Germ Cell Tumors||University of Illinois, Urbana-Champaign / Michael Spinella, Ph.D.||Reach Grants||2014||Illinois|
|Targeting PI3Kdelta in Childhood Acute Lymphoblastic Leukemia||Children's Hospital Los Angeles / Yong-mi Kim, MD & Nora Heisterkamp, PhD||Reach Grants||2015||California|
|Therapeutic Reactivation of p53 to Overcome Apoptotic Resistance in Pediatric Leukemia||Dana-Farber Cancer Institute / Loren Walensky, MD, PhD & Kimberly Stegmaier, MD||Reach Grants||2015||Massachusetts|
|Targeting Novel Pediatric-Specific FLT3 Mutations||Fred Hutchinson Cancer Research Center / Soheil Meshinchi, MD,PhD||Reach Grants||2015||Washington|
|Adoptive Immunotherapy of Tr1 Cells to Improve Outcome of Allo-HSCT Treatment for Pediatric AML||Stanford University / Maria-Grazia Roncarolo, MD & Rosa Bachetta, MD||Reach Grants||2015||California|
|Targeting PLK1 as a Common Mechanism in Ph-like ALL||University of Texas M.D. Anderson Cancer Center / Joya Chandra, PhD||Reach Grants||2016||Texas|
|LSD1 Inhibition to Treat T-cell Acute Lymphoblastic Leukemia/Lymphoma||University of Virginia, School of Medicine / Michael Engel, MD/PhD||Reach Grants||2016||Virginia|